BG106322A - 1,4,5,6-tetrahydropyrimidine derivative as vitronectin inhibitor - Google Patents

1,4,5,6-tetrahydropyrimidine derivative as vitronectin inhibitor

Info

Publication number
BG106322A
BG106322A BG106322A BG10632202A BG106322A BG 106322 A BG106322 A BG 106322A BG 106322 A BG106322 A BG 106322A BG 10632202 A BG10632202 A BG 10632202A BG 106322 A BG106322 A BG 106322A
Authority
BG
Bulgaria
Prior art keywords
ethyl
formula
ylcarbamoyl
naphthalene
compound
Prior art date
Application number
BG106322A
Other languages
Bulgarian (bg)
English (en)
Inventor
Gerhard Breipohl
Anuschirwan Peyman
Theodor Wollmann
Original Assignee
Aventis Pharma Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh
Publication of BG106322A publication Critical patent/BG106322A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/16—Nitrogen atoms not forming part of a nitro radical acylated on said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG106322A 1999-07-21 2002-01-18 1,4,5,6-tetrahydropyrimidine derivative as vitronectin inhibitor BG106322A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99114372A EP1070707A1 (en) 1999-07-21 1999-07-21 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor
PCT/EP2000/006504 WO2001007417A1 (en) 1999-07-21 2000-07-08 1,4,5,6-tetrahydropyrimidine derivative as a vitronectin inhibitor

Publications (1)

Publication Number Publication Date
BG106322A true BG106322A (en) 2002-08-30

Family

ID=8238643

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106322A BG106322A (en) 1999-07-21 2002-01-18 1,4,5,6-tetrahydropyrimidine derivative as vitronectin inhibitor

Country Status (29)

Country Link
US (1) US6900318B1 (cs)
EP (2) EP1070707A1 (cs)
JP (1) JP2003505450A (cs)
KR (1) KR20020063838A (cs)
CN (1) CN1361767A (cs)
AR (1) AR024794A1 (cs)
AT (1) ATE286030T1 (cs)
AU (1) AU775567B2 (cs)
BG (1) BG106322A (cs)
BR (1) BR0012554A (cs)
CA (1) CA2379086C (cs)
CZ (1) CZ200285A3 (cs)
DE (1) DE60017150D1 (cs)
EA (1) EA200200187A1 (cs)
EE (1) EE200200031A (cs)
HK (1) HK1048316A1 (cs)
HR (1) HRP20020057A2 (cs)
HU (1) HUP0201939A3 (cs)
IL (1) IL147396A0 (cs)
MX (1) MXPA02000674A (cs)
MY (1) MY133525A (cs)
NO (1) NO20020311D0 (cs)
NZ (1) NZ516233A (cs)
PL (1) PL353014A1 (cs)
SK (1) SK522002A3 (cs)
TR (1) TR200200116T2 (cs)
WO (1) WO2001007417A1 (cs)
YU (1) YU90201A (cs)
ZA (1) ZA200110361B (cs)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE227567T1 (de) * 1994-05-27 2002-11-15 Merck & Co Inc Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
BR9907735A (pt) * 1998-01-23 2000-10-17 Aventis Pharma Gmbh Derivados de sulfonamida como inibidores da reabsorção óssea e como inibidores da aderência celular
US6313119B1 (en) * 1998-01-23 2001-11-06 Adventis Pharma Deutschland Gmbh Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion

Also Published As

Publication number Publication date
US6900318B1 (en) 2005-05-31
YU90201A (sh) 2004-07-15
EP1204646A1 (en) 2002-05-15
MY133525A (en) 2007-11-30
AU775567B2 (en) 2004-08-05
CA2379086A1 (en) 2001-02-01
ATE286030T1 (de) 2005-01-15
AR024794A1 (es) 2002-10-23
CZ200285A3 (cs) 2003-02-12
NO20020311L (no) 2002-01-21
IL147396A0 (en) 2002-08-14
HUP0201939A2 (hu) 2002-12-28
EP1070707A1 (en) 2001-01-24
HK1048316A1 (zh) 2003-03-28
CN1361767A (zh) 2002-07-31
AU6822600A (en) 2001-02-13
SK522002A3 (en) 2003-05-02
WO2001007417A1 (en) 2001-02-01
CA2379086C (en) 2009-01-06
NZ516233A (en) 2004-07-30
EP1204646B1 (en) 2004-12-29
NO20020311D0 (no) 2002-01-21
HRP20020057A2 (en) 2003-06-30
JP2003505450A (ja) 2003-02-12
ZA200110361B (en) 2002-12-18
TR200200116T2 (tr) 2002-04-22
EE200200031A (et) 2003-02-17
DE60017150D1 (de) 2005-02-03
HUP0201939A3 (en) 2003-02-28
MXPA02000674A (es) 2002-07-30
EA200200187A1 (ru) 2002-10-31
PL353014A1 (en) 2003-10-06
BR0012554A (pt) 2002-04-16
KR20020063838A (ko) 2002-08-05

Similar Documents

Publication Publication Date Title
US5296604A (en) Proline derivatives and compositions for their use as inhibitors of HIV protease
IL149150A0 (en) 2-(4-(6-methoxy-naphthalene-2-yl)-5-pyridin-4-yl-1h-imidazole-2-yl)-2-methyl-derivatives, pharmaceutical compositions comprising them and use thereof as tie2 receptor kinase inhibitors
MX2021007251A (es) Formas polimorficas novedosas de un inhibidor de tgf?.
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
CA2476065A1 (en) Inhibitors of histone deacetylase
YU71102A (sh) Supstituisani amidi benzoeve kiseline i njihova primena kao sredstva za lečenje
IL217446A (en) Pharmaceutical preparation containing a highly purified active ingredient of 7 - chloro - 5 - hydroxy - 1 - [2 - methyl - 4 - (2 - methylbenzoyl - amino) benzoyl] - 2, 3, 4, 5 - tetrahydro - h - 1 - Benzazepine has a purity of more than 99.5% or its salt, or a drug of its salt
FI112483B (fi) Menetelmä terapeuttisesti käyttökelpoisten 3-[2-[4-(6-fluori-1,2-bentsisoksatsol-3-yyli) -1-piperidinyyli]etyyli]-2-alkyyli-pyrimidin-4-onijohdannaisten valmistamiseksi
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
JO2216B1 (en) 5 chloro-3 (4-methane sulfonyl phenyl) -6-methyl- (2.3)
Michaelides et al. Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors
CO5720995A2 (es) Compuesto novedoso
MXPA03011384A (es) Derivados de pirrolidina como inhibidores del factor xa.
ZA202407288B (en) P2x3 inhibitor compound, salt thereof, polymorph thereof and use thereof
SI1490333T1 (sl) Nove soli atorvastatina in farmacevtski sestavki, ki jih vsebujejo
BR0205683A (pt) Processo para a preparação de derivados de piperazina, e, mesilato de um composto
GB0223232D0 (en) Chemical compounds
SI1102765T1 (en) PROCESS FOR THE SYNTHESIS OF (1$i(H))-BENZO C)QUINOLIZIN-3-ONES DERIVATIVES
MY133525A (en) Ethyl(2s)-2-(naphthalene-1-sulfonylamino)-3-(4-(2-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)ethyl)benzoylamino)propionate hemifumarate, a process and intermediates for its preparation, and its use asa pharmaceutical
PL362126A1 (en) New desloratadine salts, process for their synthesis and pharmaceutical compositions thereof
AU2002339158A1 (en) 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors
EA200101109A1 (ru) Производные 1-трифторметил-4-гидрокси-7-пиперидинил-аминометилхромана
JP2010526045A (ja) Ｃｄｃ２５ホスファターゼインヒビターとしてのトリアミノピリミジン誘導体
TW200635911A (en) Sulfanyl substituted phenyl methanones
MXPA04000485A (es) Uso de acidos aril o heteroaril hidroxamicos de sulfonilo y derivados de los mismos como inhibidores de agrecanasa.